Severe Lupus Myocarditis Preceded by Mesalazine-induced Lupus

1. Katsanos K, Voulgari P, Tsianos E. Inflammatory bowel disease

and lupus: a systematic review of the literature. J Crohns Colitis 6:

735-742, 2012.

2. Vaglio A, Grayson P, Fenaroli P, et al. Drug-induced lupus: traditional and new concepts. Autoimmun Rev 17: 912-918, 2018.

3. Pretel M, Marques L, Espana A. Drug-induced lupus erythematosus. Actas Dermo-Sifiliograficas 105: 18-30, 2014.

4. Perez-Alamino R, Maldonado-Ficco H, Maldonado-Cocco J.

Rheumatic manifestations in inflammatory bowel diseases: a link

between GI and rheumatology. Clin Rheumatol 35: 291-296, 2016.

5. Aringer M, Costenbader K, Daikh D, et al. 2019 European League

Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis

78: 1151-1159, 2019.

6. Tan E, Cohen A, Fries J, et al. The 1982 revised criteria for the

classification of systemic lupus erythematosus. Arthritis Rheum

25: 1271-1277, 1982.

7. Hochberg MC. Updating the American College of Rheumatology

revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725, 1997.

8. Petri M, Orbai A, Alarcón G, et al. Derivation and validation of

the systemic lupus international collaborating clinics classification

criteria for systemic lupus erythematosus. Arthritis Rheum 64:

2677-2686, 2012.

9. Naramala S, Konala V, Adapa S, et al. Recurrent inflammatory

myositis as an extra-intestinal manifestations of dormant ulcerative

colitis in a patient on long-term mesalamine. Case Rep Gastro-

intest Med 7: 2090379, 2019.

10. Pollack A, Kontorovich A, Fuster V, Dec G. Viral myocarditisdiagnosis, treatment options, and current controversies. Nat Rev

Cardio 12: 670-680, 2015.

11. Gunnarsson I, Forslid J, Ringertz B. Mesalazine-induced lupus

syndrome. Lupus 8: 486-488, 1999.

12. Kirkpatrick AW, Bookman AA, Habal F. Lupus-like syndrome

caused by 5-aminosalicylic acid in patients with inflammatory

bowel disease. Can J Gastroenterol 13: 159-162, 1999.

13. Dent MT, Ganapathy S, Holdsworth CD, Channer KC. Mesalazine

induced lupus-like syndrome. BMJ 305: 159, 1992.

14. Gunnarsson I, Kanerud L, Pettersson E, Lundberg I, Lindblad S,

Ringertz B. Predisposing factors in sulphasalazine-induced systemic lupus erythematosus. Br J Rheumatol 36: 1089-1094, 1997.

15. Araújo-Fernández S, Ahijón-Lana M, Isenberg DA. Drug-induced

lupus: including anti-tumour necrosis factor and interferon induced. Lupus 23: 545-553, 2014.

16. Beaudoin S, Gonzalez A. Evaluation of the patient with pleural effusion. CMAJ 190: E291-E295, 2018.

17. Mai Y, Ujie H, Nishimura M, et al. Chemiluminescent enzyme immunoassay failed to detect anti-desmoglein 3 antibodies in a case

of pemphigus vulgaris. J Dermatol 44: E242-E243, 2017.

18. Mummert E, Fritzler M, Sjöwall C, Bentow C, Mahler M. The

clinical utility of anti-double-stranded DNA antibodies and the

challenges of their determination. J Immunol Methods 459: 11-19,

2018.

The Internal Medicine is an Open Access journal distributed under the Creative

Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To

view the details of this license, please visit (https://creativecommons.org/licenses/

by-nc-nd/4.0/).

Ⓒ 2023 The Japanese Society of Internal Medicine

Intern Med 62: 929-933, 2023

933

...